Literature DB >> 25174723

Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, γ-hydroxybutyric acid.

Nisha Vijay1, Marilyn E Morris.   

Abstract

γ-Hydroxybutyric acid (GHB) is widely abused in combination with other club drugs such as 3,4-methylenedioxymethamphetamine (MDMA). The objectives of this study were to characterize the effects of MDMA on GHB toxicokinetics/toxicodynamics (TK/TD) and evaluate the use of monocarboxylate transporter (MCT) inhibition as a potential treatment strategy for GHB overdose when GHB is abused with MDMA. Rats were administered GHB 400 mg/kg i.v. alone or with MDMA (5 mg/kg i.v). Effects of MDMA and of the MCT inhibitor, l-lactate, on GHB TK and sedative effects were evaluated. The results of this study demonstrated no significant effect of MDMA on GHB TK or TD. GHB plasma concentrations were unchanged, and GHB concentration-effect relationships, based on plasma and brain concentrations and the return-to-righting reflex (RRR), were similar in the presence and absence of MDMA. l-Lactate administration resulted in a significant decrease in the sedative effect (RRR) of GHB when it was coadministered with MDMA. Our results indicate that MDMA does not affect the TK/TD of GHB at the doses used in this study, and MCT inhibition using l-lactate, an effective overdose treatment strategy for GHB alone, is also effective for GHB overdose when GHB is coingested with MDMA.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  GHB; MDMA; blood-brain barrier; drug interaction; l-lactate; membrane transport/transporters; monocarboxylate transporters; overdose treatment; toxicokinetics; γ-hydroxybutyrate

Mesh:

Substances:

Year:  2014        PMID: 25174723      PMCID: PMC4175056          DOI: 10.1002/jps.24122

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  39 in total

1.  CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression.

Authors:  P Kirk; M C Wilson; C Heddle; M H Brown; A N Barclay; A P Halestrap
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

2.  Gamma hydroxybutyrate. Correlation of serum and cerebrospinal fluid levels with electroencephalographic and behavioral effects.

Authors:  O C Snead; R K Yu; P R Huttenlocher
Journal:  Neurology       Date:  1976-01       Impact factor: 9.910

3.  Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat.

Authors:  J T Lettieri; H L Fung
Journal:  J Pharmacol Exp Ther       Date:  1979-01       Impact factor: 4.030

4.  Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: relationship between in vitro transport and in vivo absorption.

Authors:  C Arena; H L Fung
Journal:  J Pharm Sci       Date:  1980-03       Impact factor: 3.534

5.  Gamma hydroxybutyrate in the monkey. I. Electroencephalographic, behavioral, and pharmacokinetic studies.

Authors:  O C Snead
Journal:  Neurology       Date:  1978-07       Impact factor: 9.910

Review 6.  Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine.

Authors:  Paul M Gahlinger
Journal:  Am Fam Physician       Date:  2004-06-01       Impact factor: 3.292

Review 7.  Gamma hydroxybutyric acid (GHB) intoxication.

Authors:  Phillip E Mason; William P Kerns
Journal:  Acad Emerg Med       Date:  2002-07       Impact factor: 3.451

8.  GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier.

Authors:  Indranil Bhattacharya; Kathleen M K Boje
Journal:  J Pharmacol Exp Ther       Date:  2004-06-01       Impact factor: 4.030

Review 9.  Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.

Authors:  Rafael de la Torre; Magí Farré; Pere N Roset; Neus Pizarro; Sergio Abanades; Mireia Segura; Jordi Segura; Jordi Camí
Journal:  Ther Drug Monit       Date:  2004-04       Impact factor: 3.681

10.  Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate-ethanol intoxication: evaluation of potential treatment strategies.

Authors:  Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2013-06-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.